Evaluate Vantage News Today

The acquisition will give Coloplast the opportunity to expand into the growing advanced wound care market.

Pharmaceutical Company Sets Gold Standard for New Drugs

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pharmaceutical stocks overall have fared well during this tough year for the ma...

BioPharma

(RTTNews) - The FDA approved three novel drugs in March, bringing the total number of novel drug approvals this year to ten. Now, lets take a lo...

INN takes a closer look at the first half of 2021 for the biotech industry and the key trends investors need to know about so far this year.

BioPharma

Wednesday, 20 January 2021, 4:03 pm The year 2021 is set to become quite a year for the pharma companies leading the COVID-19 vaccine race, with significant revenues on the line. As some of the most significant players in the market, pharma giants Pfizer and Moderna are set for the lions share of 2021 vaccine sales. According to data presented by Finaria.it, BioNTech-Pfizer and Moderna COVID-19 vaccines sales are expected to generate $14.7bn in revenue by 2023. Moderna COVID-19 Vaccine Sales R...

Press Release – Psychic Ventures Ltd The year 2021 is set to become quite a year for the pharma companies leading the COVID-19 vaccine race, with significant revenues on the line. As some of the most significant players in the market, pharma giants Pfizer and Moderna are set for the …The year 2021 is set to become quite a year for the pharma companies leading the COVID-19 vaccine race, with significant revenues on the line. As some of the most significant players in the market, pharma gian...

Evaluate Ltd.: Evaluate Vantage 2021 Preview: High Hopes and Valuations Set the Tone for Biopharma Evaluate Vantage 2021 Preview, published today Sales of COVID-19 vaccines are expected to reach between $10-15bn next year, and for now Modernas mRNA-1237 is the favored candidate among equity analysts, despite BioNTech and Pfizers first mover advantage. With many leading COVID-19 projects due to yield data next year, it should become clearer which companies will deliver clinically and commerciall...